What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Surgery
Dominick J. Angiolillo focuses on Clopidogrel, Internal medicine, Cardiology, Aspirin and Percutaneous coronary intervention.
His research integrates issues of Platelet activation, Platelet and Anesthesia in his study of Clopidogrel.
Dominick J. Angiolillo has researched Internal medicine in several fields, including Diabetes mellitus and Endocrinology.
Dominick J. Angiolillo combines subjects such as Stroke, Thrombosis, Randomized controlled trial and Stent with his study of Cardiology.
His studies deal with areas such as Regimen, Pharmacotherapy, Antithrombotic and Clinical trial as well as Aspirin.
His studies examine the connections between Percutaneous coronary intervention and genetics, as well as such issues in Conventional PCI, with regards to Pharmacodynamics.
His most cited work include:
- Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. (1060 citations)
- Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate (956 citations)
- Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives (824 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Cardiology, Clopidogrel, Percutaneous coronary intervention and Aspirin.
His study in Coronary artery disease, Acute coronary syndrome, Myocardial infarction, Ticagrelor and Platelet is done as part of Internal medicine.
His studies in Cardiology integrate themes in fields like Diabetes mellitus and Thrombosis, Surgery.
His research investigates the connection with Clopidogrel and areas like Platelet aggregation inhibitor which intersect with concerns in Ticlopidine.
His work carried out in the field of Percutaneous coronary intervention brings together such families of science as Angioplasty, Randomized controlled trial, Conventional PCI and Intensive care medicine.
His Aspirin study combines topics in areas such as Gastroenterology and Clinical trial.
He most often published in these fields:
- Internal medicine (62.52%)
- Cardiology (44.34%)
- Clopidogrel (41.82%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (62.52%)
- Cardiology (44.34%)
- Percutaneous coronary intervention (27.69%)
In recent papers he was focusing on the following fields of study:
Dominick J. Angiolillo mainly investigates Internal medicine, Cardiology, Percutaneous coronary intervention, Ticagrelor and Aspirin.
His work on Myocardial infarction, Acute coronary syndrome, Clopidogrel and P2Y12 as part of general Internal medicine study is frequently linked to In patient, therefore connecting diverse disciplines of science.
Clopidogrel is closely attributed to CYP2C19 in his study.
His Percutaneous coronary intervention study integrates concerns from other disciplines, such as Conventional PCI, Antithrombotic, Stent and Clinical endpoint, Randomized controlled trial.
His Ticagrelor research includes themes of Diabetes mellitus, Pharmacodynamics, Prasugrel and Hazard ratio.
The various areas that Dominick J. Angiolillo examines in his Aspirin study include Platelet and Pharmacology.
Between 2017 and 2021, his most popular works were:
- Ticagrelor with or without Aspirin in High-Risk Patients after PCI (255 citations)
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention : A Consensus Document From the Academic Research Consortium for High Bleeding Risk (189 citations)
- Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention (133 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Surgery
His main research concerns Internal medicine, Percutaneous coronary intervention, Ticagrelor, Myocardial infarction and Cardiology.
His study in Clopidogrel, Acute coronary syndrome, Aspirin, Stroke and P2Y12 is carried out as part of his studies in Internal medicine.
Dominick J. Angiolillo has included themes like CYP2C19 and Coagulation in his Clopidogrel study.
His Percutaneous coronary intervention research includes elements of Platelet aggregation inhibitor, Clinical trial, Conventional PCI, Antithrombotic and Coronary artery disease.
He combines subjects such as Platelet activation, Placebo, Clinical endpoint and Kidney disease with his study of Myocardial infarction.
Dominick J. Angiolillo works mostly in the field of Cardiology, limiting it down to concerns involving Platelet and, occasionally, Drug Substitution.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
